Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by skyhigh123on Oct 01, 2018 4:35pm

95 Views

Post# 28724602

Our latest Patent

Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis

Publication number: 20180237374

Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, For OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.

Type: Application

Filed: April 4, 2018

Publication date: August 23, 2018

Inventors: Boulos ZACHARIE, Shaun ABBOTT, Lyne GAGNON, Pierre LAURIN, Brigitte GROUIX

Bullboard Posts

FLYHT and WestJet partner on weather forecasting